The Pharmaletter
Angelini Pharma
Founding and History
Angelini’s pharmaceutical operations trace back to the wider Angelini group’s long-standing presence in healthcare. In recent years, Angelini Pharma has expanded its branded prescription footprint in brain health through acquisitions and licensing, including the acquisition of Arvelle Therapeutics, which strengthened its epilepsy portfolio and European CNS presence. In January 2026, Angelini Pharma appointed Sergio Marullo di Condojanni as chief executive officer.
Therapy Areas and Focus
Angelini Pharma’s business is organized around three main areas:
- Brain Health, including mental health and epilepsy
- Specialty and Primary Care medicines
- Consumer Healthcare (OTC and self-care products)
Technology Platforms and Modalities
Angelini Pharma operates as a branded medicines company rather than a single-technology biotech. Its capabilities are centered on:
Commercialization and lifecycle management of established and differentiated medicines
Development and registration planning for select late-stage assets, often via in-licensing or acquisitions
Building country medical, market access, and commercial capabilities in targeted therapy areas
In epilepsy, Angelini markets cenobamate in Europe under the brand Ontozry, added through the Arvelle acquisition and related licensing structure.
Key Personnel
Sergio Marullo di Condojanni, Chief Executive Officer (appointed January 2026)
Strategic Partnerships
Angelini Pharma uses a combination of in-licensing, acquisitions, and regional partnerships to build and expand its portfolio. The Arvelle transaction is a key example of this approach in brain health, bringing European commercialization rights and infrastructure around an epilepsy product into the group.
FAQ Section
Angelini Pharma is a branded pharmaceutical company that develops, registers, and commercializes prescription medicines and consumer healthcare products. It builds portfolios through internal development, licensing, and acquisitions, supported by country affiliates and partner networks.
The company’s core focus areas are brain health (notably mental health and epilepsy), specialty and primary care medicines, and consumer healthcare.
Angelini Pharma’s portfolio spans prescription and consumer products across its focus areas. In epilepsy, it commercializes cenobamate in Europe as Ontozry for adults with drug-resistant focal-onset seizures, representing a flagship brain health product in its current portfolio mix.
In January 2026, Angelini Pharma announced the appointment of Sergio Marullo di Condojanni as chief executive officer. Recent years have also been defined by portfolio expansion in brain health, including the acquisition of Arvelle Therapeutics, which added an epilepsy commercialization platform in Europe.
Angelini Pharma’s business is primarily commercialization- and lifecycle-led. Clinical evidence for key marketed medicines is typically generated through the original development programs and regulatory submissions, with Angelini’s role often focused on regional commercialization, medical implementation, and post-launch lifecycle activities rather than routinely publishing pivotal trial readouts under its own name.
Regulatory milestones are typically product- and country-specific, focused on maintaining registrations, securing new market authorizations, and executing lifecycle plans such as label updates, line extensions, and geographic expansion for priority brands in brain health and other focus areas.
Angelini Pharma is led by an executive team aligned to a multi-country branded medicines model, with capabilities spanning medical affairs, market access, regulatory, supply, and commercial execution. The January 2026 CEO appointment reflects group-level leadership alignment across Angelini Industries and its pharmaceutical business.
Latest Angelini Pharma News
| Headless Content Management with Blaze